Acerus Pharmaceuticals Corporation
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Edward Gudaitis
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 7025 Langer Drive Mississauga ON Canada L5N 0E8
- IPO Date
- Apr 18, 2012
- Website
- aceruspharma.com
- Similar Companies
- Business
- Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the development, manufacture, marketing, and distribution of branded products primarily in the men's health sector. The company's core product is NATESTO, a testosterone replacement therapy delivered via a nasal gel; it also engages in the commercialization of additional innovative pharmaceutical products aimed at improving patient experience. Acerus operates mainly in the United States and Canada, leveraging its direct salesforce and global network of licensed distributors. Founded in 2003 and headquartered in Toronto, Canada, Acerus targets endocrinology and urology healthcare providers as key customer segments. In the last two years, Acerus has undergone significant operational and strategic changes, including entering creditor protection under the Companies' Creditors Arrangement Act (CCAA) in early 2023. The company finalized a transaction with First Generation Capital Inc., which emerged as the successful bidder in its sale and investment solicitation process. Acerus also established a commercial agreement with Verity Pharmaceuticals for the exclusive promotion of NATESTO in Puerto Rico, leveraging Verity's salesforce and healthcare network. Additionally, Acerus has a co-promotion agreement with Amneal Pharmaceuticals to promote NATESTO in the U.S. endocrinology segment through mid-2024, broadening its market footprint. The company has implemented cash conservation measures, including downsizing its U.S. sales force, while focusing on maintaining market access for its flagship product amid financial restructuring. Acerus Pharmaceuticals is engaged in ongoing efforts to expand and enhance its product portfolio and commercial reach within the specialty pharmaceutical industry, particularly in testosterone therapies and related men's health treatments. The company also manages loan agreements to support its operations during financial restructuring and continues collaborations to optimize commercialization efforts across North American markets. Its subsidiaries include Acerus Pharmaceuticals USA, LLC, and it maintains strategic relationships with multiple partners to bolster product distribution and market penetration. The company remains focused on innovation, regulatory compliance, and financial recovery initiatives to support long-term growth.
China Pharma (NYSE:CPHI) & Acerus Pharmaceuticals (OTCMKTS:ASPCF) Financial Comparison
Critical Review: Acerus Pharmaceuticals (OTCMKTS:ASPCF) vs. Zymeworks (NASDAQ:ZYME)
Acerus Update
Acerus Pharmaceuticals Corporation (ASPCF) CEO Edward Gudaitis on Q2 2022 Results - Earnings Call Transcript
Acerus to Report Q2-2022 Financial Results and Host Investor Call
Acerus To Report Q4 And Full Year 2021 Financial Results And Host Investor Call
Acerus Pharmaceuticals Corporation (ASPCF) CEO Ed Gudaitis on Q3 2021 Results - Earnings Call Transcript
Acerus to Report Q3-2021 Financial Results and Host Investor Call
Acerus Announces Participation in HC Wainwright Conference
Acerus Reports Acceptance of Part 36 Settlement Offer in Recipharm Litigation
Acerus Pharmaceuticals Corporation (ASPCF) CEO Ed Gudaitis on Q2 2021 Results - Earnings Call Transcript
Acerus Reports Fiscal 2021 Second Quarter Financial Results
Acerus to Report Q2-2021 Financial Results and Host Investor Call
Acerus Provides Update on Litigation with Recipharm
Acerus Announces New PBM Contract, Significantly Expanding NATESTO® Insurance Coverage in the United States